Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)

Peter Foley; Nick Manuelpillai; Con Dolianitis; Geoffrey D Cains; Eric Mate; Rebecca Tronnberg; Christopher Baker

doi:10.1111/ajd.13895

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)

Australas J Dermatol. 2022 Aug;63(3):303-311. doi: 10.1111/ajd.13895. Epub 2022 Jul 9.

Authors

Peter Foley^{1

2}, Nick Manuelpillai¹, Con Dolianitis^{2

3}, Geoffrey D Cains⁴, Eric Mate⁵, Rebecca Tronnberg⁵, Christopher Baker^{1

2}

Affiliations

¹ Skin Health Institute, Carlton, Victoria, Australia.
² The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.
³ Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁴ Liverpool Hospital, Sydney, New South Wales, Australia.
⁵ Novartis Pharmaceuticals, Australia Pty Limited, Macquarie Park, New South Wales, Australia.

Abstract

Background: Drug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long-term effectiveness, safety, and real-world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaque psoriasis (CPP) in the Australian clinical setting.

Methods: Data of all patients (aged ≥18 years) from Australasian Psoriasis Registry (APR) treated with secukinumab were analysed. The primary objective was to describe the drug survival of secukinumab at 9 months. Key secondary objectives included drug survival of secukinumab at 3, 6, 15, and 21 months, stratified by biologic-naïve vs biologic-experienced patients; proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75/90/100 responses; and changes in health-related quality of life over time utilising the Dermatology Life Quality Index (DLQI).

Results: Of 294 patients included in this analysis, 110 (37.4%) were biologic-naïve and 184 (62.6%) biologic-experienced. Kaplan-Meїer drug survival rates in biologic-naïve vs biologic-experienced patients were 0.92 vs. 0.86 (9 months) and 0.82 vs. 0.68 (21 months), respectively. The proportion of patients with PASI 75/90/100 responses for biologic-naïve vs. biologic-experienced was 100/87.7/38.4 vs 98.5/61.5/27.2 (9 months) and 100/81.0/41.7 vs. 98.4/62.0/24.2 (21 months), respectively. The mean (standard deviation [SD]) DLQI in biologic-naïve vs. experienced patients was 2.2 (4.1) vs. 3.1 (5.2) (9 months) and 1.4 (2.5) vs. 3.1 (5.3) (21 months). No new safety signals were observed.

Conclusions: Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real-world setting, in biologic-naïve and biologic-experienced patients with severe CPP.

Keywords: Australia; drug survival; durability; psoriasis; real-world and clinical setting; secukinumab.

MeSH terms

Adolescent
Adult
Antibodies, Monoclonal, Humanized
Australia
Biological Products* / therapeutic use
Humans
Psoriasis* / drug therapy
Quality of Life
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Biological Products
secukinumab

Abstract

MeSH terms

Substances

Grants and funding